We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients in the program can get a maximum of $57,432 back if they take the drug for three months and can show that they experienced no benefit. Read More
Pfizer has quietly launched what it’s calling the Pfizer Pledge, a pilot program that attaches an insurance-backed warranty to the performance of the company’s 10-year-old lung cancer drug Xalkori, promising money back. Read More
Bayer is investing in GRO Biosciences, a Boston-based company that is developing protein therapeutics for patients with autoimmune and metabolic diseases. Read More
Novartis has teamed up with Cambridge, UK-based Dunad Therapeutics to develop protein degradation therapies in a deal potentially worth more than $1.3 billion. Read More
Metagenomi will receive an undisclosed upfront payment, along with an equity investment, research funding and milestones-based payments for unspecified disease targets. Read More
Merck has inked a deal worth more than $525 million with preclinical biotech Synthekine to develop and commercialize novel cytokine therapeutics that focus on autoimmune diseases. Read More
Johnson & Johnson (J&J) has settled “substantially all” of the thousands of Risperdal (risperidone)-related lawsuits filed in the U.S. — which had alleged that the company’s anti-psychotic drug caused males to grow breast tissue. Read More
In 2018, Aegerion entered into a $40 million settlement with the Justice Department over charges that it marketed Juxtapid for uses the FDA never approved. Read More